Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Boehringer Ingelheim announced that survodutide, a dual-action drug that works like both glucagon and GLP-1 (weight-loss hormones), helped people lose 16.6% of their body weight in a Phase III trial (a large late-stage test). The drug also improved other health markers related to metabolism in people with obesity or excess weight.

• •Survodutide hit 16.6% weight loss in Phase III obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial showed metabolic improvements in obesity/overweight patients

Boehringer Ingelheim's survodutide, a GLP-1 dual agonist (a type of weight-loss and diabetes drug), showed positive results in a large Phase 3 trial (a major test required before FDA approval). The company is advancing the drug toward regulatory approval based on these successful trial results.

• •Boehringer Ingelheim's survodutide hit positive results in a Phase 3 trial
• •Survodutide is a GLP-1/glucagon dual agonist for weight loss and diabetes
• •Company advancing the drug toward regulatory approval

Survodutide, a drug that works on two different body signals to reduce weight, showed strong results in a Phase 3 trial (a large test needed before the FDA considers approval). The trial tested whether survodutide could help people with obesity lose weight.

• •Survodutide met endpoints in a Phase 3 obesity trial
• •Drug is a dual agonist mechanism
• •Trial tested weight loss in patients with obesity

• •Survodutide is described as a dual agonist tested against semaglutide